Recently, Sutro Biopharma announced that the US Food and Drug Administration (FDA) has granted STRO-001 the orphan drug qualification for the treatment of multiple myeloma (MM). STRO-001 is a potential first antibodyRead More…
Still reeling from the failure of its lead breast cancer candidate glembatumumab vedotin last month, Celldex has culled another two pipeline projects and now says it will focus its R&D efforts mainlyRead More…
The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer, has completed full enrollment andRead More…
Antibody-drug conjugates or ADCs have emerged as a powerful and strategic tool in the targeted treatment of cancer. These relatively novel agents combine the ability of monoclonal antibodies to specifically target tumor cells,Read More…
A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company’s the operating results for 2017. Immunogen is a clinical-stage biotechnologyRead More…